Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

Cochrane Review Uncertain on Myo-Inositol for PCOS Live Births; IVF Pregnancy Rates May Improve Slightly

November 21, 2026 Health Desk Health

A Cochrane review updated with evidence current to 10 November 2025 finds insufficient data to determine whether myo-inositol helps women with polycystic ovary syndrome have a baby, though it may slightly increase clinical pregnancy rates during in vitro fertilisation.

What the updated review found

The review, which updates a 2018 assessment, analysed 21 studies involving 1,634 women with PCOS conducted in Iran, India, Italy, Albania, Germany, and Vietnam. Cochrane reported that for women undergoing ovulation induction or intrauterine insemination, a single study of 120 women left reviewers unsure about effects on live birth, pregnancy, miscarriage, multiple pregnancy, ovarian hyperstimulation syndrome, or gestational diabetes.

For women undergoing IVF, evidence from two studies totalling 84 women left reviewers uncertain about live birth and miscarriage rates compared with no treatment. However, three studies involving 164 women suggested myo-inositol may slightly improve clinical pregnancy rates confirmed by ultrasound. Compared with an expected 15% pregnancy rate without treatment, the chance with myo-inositol ranged from 15% to 46%, Cochrane reported.

One study of 102 women comparing myo-inositol with metformin left reviewers uncertain about effects on live birth, clinical pregnancy, miscarriage, or ovarian hyperstimulation syndrome. The review said that few studies reported the outcomes that matter most to women, such as having a baby or treatment side effects.

Conflicting meta-analysis reports higher pregnancy rates

A separate systematic review and meta-analysis published in May 2025 in the International Journal of Reproductive Biomedicine reached a more positive conclusion on clinical pregnancy. Researchers from Iran University of Medical Sciences, Birjand University of Medical Sciences, and Kurdistan University of Medical Sciences analysed 17 intervention studies from databases covering January 2000 to 2023.

That meta-analysis found myo-inositol or D-chiro-inositol supplementation significantly increased clinical pregnancy rates (risk ratio 1.64, 95% CI 1.25–2.15) and top-grade embryo rates (risk ratio 1.12, 95% CI 1.02–1.23). However, it also reported reductions in antral follicle count (weighted mean difference -0.78, 95% CI -1.07 to -0.49) and anti-Müllerian hormone levels (weighted mean difference -0.46, 95% CI -0.67 to -0.25).

The Iranian research team, led by Sene AA and Saeedzarandi M, concluded the findings provide reliable evidence on fertility and ovarian function in women with PCOS undergoing assisted reproductive technology. The study was published 1 May 2025 with DOI 10.18502/ijrm.v23i5.19260.

Why the evidence remains uncertain

Cochrane reviewers rated their confidence in the evidence as low or very low because studies included few women, reported few events, or had design weaknesses. Most trials examined myo-inositol; few assessed D-chiro-inositol, and those that did reported no usable results. No studies compared different inositol types directly across the full range of fertility treatments, including natural conception attempts.

The condition, renamed polyendocrine metabolic ovarian syndrome in 2026, affects about one in eight women worldwide. It disrupts ovulation through hormonal imbalance and insulin resistance. Inositol, a naturally occurring substance in fruits, nuts, and beans also synthesised from glucose, is thought to improve insulin sensitivity and ovarian function, though the optimal isomer, dosage, and treatment window remain undefined.

Gaps in the research

Neither review identified funding sources for the included trials. The Cochrane review explicitly calls for better studies covering different stages of fertility treatment and women trying to conceive naturally. The Iranian meta-analysis said that only a small number of systematic reviews had been published in the preceding three to four years, emphasising the need for updated evidence synthesis.

Cochrane, founded in 1993 under Iain Chalmers in response to Archie Cochrane’s call for systematic reviews of randomised trials, is a British charitable organisation with over 37,000 volunteer experts worldwide. Its reviews are published in the Cochrane Library and are widely regarded for methodological rigour; a 2004 editorial in the Canadian Medical Association Journal described them as the best single resource for methodologic research and meta-epidemiology.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

More on this

  • Image-Guided Programming Halves DBS Setup Time Versus Local Field Potentials Without Losing Clinical Benefit
  • Study Links Regular Coffee Consumption to Gut Changes
  • Real Rates, Not Inflation Bets, Drove the 10-Year Yield to a 2002 High (daybreakwire.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service